Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: phase 1/2 study. The Pediatric AIDS Clinical Trials Group Protocol 351 Study Team.

Shearer, W T; Israel, R J; Starr, S; Fletcher, C V; Wara, D; Rathore, M; Church, J; DeVille, J; Fenton, T; Graham, B; Samson, P; Staprans, S; McNamara, J; Moye, J; Maddon, P J; Olson, W C

Shearer, W T; Israel, R J; Starr, S; Fletcher, C V; Wara, D; Rathore, M; Church, J; DeVille, J; Fenton, T; Graham, B; Samson, P; Staprans, S; McNamara, J; Moye, J; Maddon, P J; Olson, W C.

Affiliation

Shearer WT; Dept. of Pediatrics-Allergy/Immunology, Baylor College of Medicine, Houston, TX 77030, USA. wshearer@bcm.tmc.edu

J Infect Dis ; 182(6): 1774-9, 2000 Dec.

Article in En | MEDLINE | ID: mdl-11069253

Subject(s)

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Recombinant Fusion Proteins / HIV Infections / HIV-1 / CD4 Immunoadhesins / Anti-HIV Agents Type of study: Guideline Limits: Adolescent / Child / Child, preschool / Female / Humans / Male Language: En Journal: J Infect Dis Year: 2000 Document type: Article Affiliation country: Estados Unidos Country of publication: Estados Unidos

Search on Google

Add to My VHL

XML

PubMed Links